Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01058174
Other study ID # 9463-EC-0001
Secondary ID 2008-005214-49
Status Completed
Phase Phase 3
First received
Last updated
Start date December 15, 2009
Est. completion date May 3, 2012

Study information

Verified date March 2019
Source Astellas Pharma Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prevention of invasive fungal infection in high risk patients following liver transplant.


Description:

After receiving liver transplant, subjects will be randomized to one of the two treatment arms.

Study drugs will be administered for a period of 21 days, or until hospital discharge, whichever occurs first.

Additionally, mortality data will be collected at the Long-term Follow-up.


Recruitment information / eligibility

Status Completed
Enrollment 350
Est. completion date May 3, 2012
Est. primary completion date May 3, 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Undergoing orthotopic whole or split liver allograft transplantation

- Patients at 'high risk' of invasive fungal infection due to the presence of at least one of the following risk factors:

- Re-transplantation

- Acute liver failure

- Pre- or post-operative renal impairment (defined as creatinine clearance =40 ml/min) or need for renal replacement therapy

- Admission to Intensive Care Unit (ICU) for greater than 48 hours prior to liver transplant

- Re-operation (abdominal surgery) within 5 days of liver transplant

- Presence of choledocojejunostomy

- Perioperative colonization with fungi, defined as two or more positive clinical site surveillance cultures for Candida spp., obtained within 96 hours before or after liver transplant

- Need for prolonged mechanical ventilation for greater than 48 hours following liver transplant

- Transfusion intraoperatively of 20 or more units of cellular blood products

- Female subject of childbearing potential must have a negative urine or serum pregnancy test prior to randomization and must agree to maintain effective birth control during the study

Exclusion Criteria:

- Any systemic antifungal therapy (excluding fluconazole or oral nystatin for a maximum of 7 days) within 14 days prior to randomization

- Evidence of documented ('proven' or 'probable') or suspected ('possible') IFD (according to the EORTC/MSG criteria)

- Allergy, hypersensitivity, or any serious reaction to an echinocandin antifungal, or any of the study drugs or their excipients

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
micafungin
intravenous infusion
fluconazole
intravenous infusion
liposomal amphotericin B
intravenous infusion
caspofungin
intravenous infusion

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Astellas Pharma Inc

Countries where clinical trial is conducted

Austria,  Belgium,  France,  Germany,  Hungary,  Ireland,  Italy,  Portugal,  Romania,  Russian Federation,  Saudi Arabia,  Spain,  Sweden,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary 'Clinical success' at the End of Prophylaxis as assessed by the Independent Data Review Board (IDRB). up to 21 days
Secondary Absence of a 'proven' or 'probable' Invasive Fungal Disease (IFD) at the End of Study as assessed by the IDRB 3 months
Secondary Absence of 'proven' or 'probable' IFD at the End of Prophylaxis and at the End of Study as assessed by the Investigator up to 21 days & 3 months
Secondary Time to 'proven' or 'probable' IFD up to 3 months
Secondary Fungal free survival at the End of Study and at the end of Long-term Follow-up 3 months & 6 months
Secondary Incidence of superficial fungal infection and colonization at the End of Prophylaxis as compared to Baseline up to 21 days
See also
  Status Clinical Trial Phase
Completed NCT04180735 - Intestinal Perforation in Patients Receiving an Orthtopic Liver Transplantation in the Montpellier University Hospital
Completed NCT01011205 - Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation Phase 3
Completed NCT01888432 - Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants Phase 3
Recruiting NCT04203004 - HOPE With Cytokine Filtration in Liver Transplantation (Cyto-HOPE) N/A
Recruiting NCT04564313 - Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation Phase 1
Withdrawn NCT03596970 - Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients. Phase 3
Not yet recruiting NCT02544906 - Propofol Versus Dexmedetomidine for Prevention of Sevoflurane Agitation in Recipients of Living Donor Liver Transplantation N/A
Completed NCT03133065 - Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs Phase 4
Recruiting NCT01705015 - Organ Transplantation Rehabilitation: Effect of Bedside Exercise Device and Activity Reinforcement N/A
Completed NCT01425385 - Autoregulation Assessment During Liver Transplantation N/A
Completed NCT01655563 - Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation Phase 2
Terminated NCT01445236 - Pilot Study of Immunosuppression Drug Weaning in Liver Recipients Exhibiting Biomarkers of High Likelihood of Tolerance N/A
Completed NCT00938860 - Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C Phase 4
Completed NCT00531921 - Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival N/A
Terminated NCT00585858 - Cytokine Kinetics Test to Assess the Presence or Absence of Tolerance in Organ Transplant N/A
Withdrawn NCT00585429 - Evaluation of Kidney Disease in Liver Transplant Recipients N/A
Completed NCT00456235 - Reduction in the Risk of Rejection by Mycophenolate Mofetil Dose Adjustment in Liver Transplant Patients With Side Effects Caused by the Calcineurine Inhibitors Phase 4
Recruiting NCT00147459 - Immunogenicity of Booster Hepatitis B Vaccines in Children After Liver Transplantation N/A
Withdrawn NCT00167492 - Enteric Coated Myfortic for Liver Transplant Recipients Phase 4
Terminated NCT00161356 - Ambisome in Liver Transplant Patients Phase 4